<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841604</url>
  </required_header>
  <id_info>
    <org_study_id>Z7219M01</org_study_id>
    <nct_id>NCT03841604</nct_id>
  </id_info>
  <brief_title>Effect of Safinamide on Parkinson's Disease Related Chronic Pain</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zambon SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV, international, multicentre, randomised, double-blind, placebo controlled
      study in IPD patients, experiencing motor fluctuations and PD related chronic pain while on
      stable doses of levodopa (L-Dopa).

      Participants will be randomized 2:1 to receive either active or placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international, multicentre, randomised, double-blind, placebo-controlled study.

      Patients will be randomized 2:1 to receive either active and placebo Approximately 220
      participants will be screened, of which 177 will be enrolled Study participation will be up
      to a maximum duration of 19 weeks and will comprise a screening period (1 to 2 weeks) and a
      treatment period (16 weeks). A telephone follow-up call will be performed 1 week after the
      end of treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Anticipated">June 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the potential efficacy of safinamide 100 mg od, compared to placebo, as add-on therapy, for PD related chronic pain: Numerical Rating Scale (NRS)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in pain severity (&quot;average worst pain experienced in the last 7 days&quot;), as assessed by an 11-point Numerical Rating Scale (NRS).
[0 point is the minimum and 10 point is the maximum. The higher the score, the more severe the pain]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of pain responders</measure>
    <time_frame>16 weeks</time_frame>
    <description>Reduction in pain severity of ≥2 points (&quot;average worst pain experienced in the last 7 days&quot;) as assessed by an 11-point NRS, compared to baseline [0 point is the minimum and 10 point is the maximum. The higher the score, the more severe the pain]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression for pain (change)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in the CGI-C (Clinical Global Impression - Change) score for pain [ a seven-point scale, it ranges from Very much Improved to Very much Worse]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression for pain (severity)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The CGI-S (Clinical Global Impression - Severity) score for pain at week 16 [ a seven-point scale, it ranges from Very much Better to Very much Worse]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression for pain</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in the PGI-C (Patient Global Impression - Change) score for pain
[ a seven-point scale, it ranges from Very much Better to Very much Worse]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of pain drugs (Percentage)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percentage of reduction in number of concomitant pain drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of pain drugs (amount)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Amount of PRN pain medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of pain drugs</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of patients with at least one intake of PRN pain medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in the Hospital Anxiety and Depression Scale (HADS) score
[Fourteen item scale, seven items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor and non-motor symptoms</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in the MDS-UPDRS (total score and subscores)
[The MDS-UPDRS has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living, Part III (motor examination) and Part IV (motor complications)]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Idiopathic Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safinamide methanesulfonate film coated tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Safinamide methanesulfonate matching placebo film coated tablets once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide Methanesulfonate</intervention_name>
    <description>50 mg, 100 mg</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide methanesulfonate matching placebo</intervention_name>
    <description>50 mg, 100 mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant must be 30 years of age or older, at the time of signing the informed
             consent.

          2. Diagnosed with IPD by using the United Kingdom Parkinson's Disease Society Brain Bank
             criteria for more than 5 years duration.

          3. Receiving treatment with a stable dose of oral L-Dopa (including controlled release
             [CR], immediate release [IR] or a combination of CR/IR), with and without
             benserazide/carbidopa, with or without addition of a catechol O-methyltransferase
             (COMT) inhibitor and may be receiving concomitant treatment with stable doses of a
             dopamine agonist, an anticholinergic and/or amantadine for at least 4 weeks prior to
             the randomisation (baseline visit).

          4. Hoehn and Yahr stage between 2-3 (inclusive) during the &quot;ON&quot; phase at the screening
             visit.

          5. Experiencing motor fluctuations following optimum titration of treatment medications
             and within the 4 weeks immediately prior to randomisation.

          6. Experiencing chronic pain (i.e. ongoing for ≥3 months prior to screening visit); the
             Investigator must consider chronic pain directly related to PD and not explained by
             any other health problem (e.g. peripheral neuropathy, organ disease or arthritis pain)
             OR consider the intensity of chronic pain specifically aggravated by PD.

          7. If taking regular analgesics, the treatment regimen should be stable in the 4 weeks
             prior to the randomisation visitt.

          8. Able to maintain an accurate and complete electronic diary with the help of a
             caregiver.

          9. Male or female

             •A female participant is eligible to participate if she is not pregnant, not
             breastfeeding, and at least one of the following conditions applies: i.Not a woman of
             childbearing potential (WOCBP) OR ii.A WOCBP who agrees to follow the contraceptive
             guidance

         10. Capable of giving signed informed consent

        Exclusion Criteria:

          1. Any form of Parkinsonism other than IPD.

          2. Diagnosis of chronic migraine (&gt;15 days per month) or cancer pain.

          3. History of bipolar disorder, depression, schizophrenia or other psychotic disorder
             requiring treatment with neuroleptics.

          4. History of dementia or cognitive dysfunction.

          5. Severe, peak dose or biphasic dyskinesia.

          6. Unpredictable or widely swinging fluctuations.

          7. Ophthalmologic history including any of the following conditions: albinism, uveitis,
             retinitis pigmentosa, retinal degeneration, active retinopathy, severe progressive
             diabetic retinopathy, inherited retinopathy or family history of hereditary retinal
             disease.

          8. Moderate or severe liver failure using the Child-Pugh classification score.

          9. History of drug and/or alcohol abuse within 12 months prior to screening as defined by
             the current edition of the Diagnostic and Statistical Manual of Mental Disorders.

         10. Allergy/sensitivity, intolerance or contraindications to Safinamide.

         11. Treatment with monoamine oxidase inhibitors (MAOIs), levodopa infusion, pethidine,
             fluoxetine, fluvoxamine less than 4 weeks prior to the randomisation visit

         12. Use of any investigational drug or device within 30 days prior to screening or 5
             half-lives, whichever is the longest

         13. Previous treatment with Safinamide in the 9 months before the screening visit

         14. Mini-Mental State Exam (MMSE) total score &lt;24 at screening.

         15. NRS score ≤ 4 points at randomization visit.

         16. Any clinically significant condition which, in the opinion of the Investigator, would
             not be compatible with study participation or represent a risk for participants while
             in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Viviana Tubazio</last_name>
    <phone>+39 026652.4414</phone>
    <email>viviana.tubazio@zambongroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative site</name>
      <address>
        <city>Wien</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13088</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Dresde</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45257</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Gera</city>
        <zip>07551</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medicine Göttingen Germany</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Haag</city>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NeuroPoint Akademie</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele S.r.l. - PPDS</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Neurologico Mediterraneo Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00148</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Salerno</city>
        <zip>84084</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>C.A.U de Burgos - Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Donostia</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital HM Puerta del Sur</name>
      <address>
        <city>Madrid</city>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

